Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes

Table 1

Clinical data of neovascular AMD cohort. The following abbreviations are used: BCVA: best-corrected visual acuity; CMT: central macular thickness; IV: intravitreal injections.

(a)

Clinical data
	BCVA baseline	BCVA 1 y	BCVA 2 y	CMT baseline	CMT 1 y	CMT 2 y	N. IV 1 y	N. IV 2 y	TOT N. IV
Mean	0.46	0.40	0.42	380	334	307	6.1	3.5	9.6
STD	0.33	0.37	0.38	118	93	62	1.7	2.1	3.8

(b)

Clinical data
value	BCVA	CMT
Baseline vs 1 y	0.001	0.001
Baseline vs 2 y	0.01	0.001
1 y vs 2 y	0.04	0.01